| Literature DB >> 32856592 |
S N Gonzalez-Diaz1, R V Villarreal-Gonzalez1, C E De Lira-Quezada1, G K Rocha-Silva1, V M Oyervides-Juarez2, O Vidal-Gutierrez2.
Abstract
Entities:
Keywords: Adenocarcinoma; Anaphylaxis; Atezolizumab; Bevacizumab; Desensitization
Mesh：
Substances：
Year: 2020 PMID： 32856592 DOI： 10.18176/jiaci.0637
Source DB: PubMed Journal: J Investig Allergol Clin Immunol ISSN： 1018-9068 Impact factor: 4.333